US Stock MarketDetailed Quotes

OKUR OnKure Therapeutics

Watchlist
  • 4.610
  • -0.010-0.22%
Close Mar 14 16:00 ET
  • 4.610
  • 0.0000.00%
Post 16:00 ET
61.94MMarket Cap-1.17P/E (TTM)

About OnKure Therapeutics Company

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Company Profile

SymbolOKUR
Company NameOnKure Therapeutics
Listing DateApr 9, 2021
Issue Price15.00
CEODr. Nicholas A. Saccomano, PhD
MarketNASDAQ
Employees46
Fiscal Year Ends12-31
Address6707 Winchester Circle,Suite 400
CityBoulder
ProvinceColorado
CountryUnited States of America
Zip Code80301
Phone1-702-307-2892

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Nicholas A. Saccomano, PhD
  • Director, President and Chief Executive Officer
  • 9.52M
  • Dr. Samuel Agresta, M.D.,M.P.H.
  • Chief Medical Officer
  • 2.84M
  • Dr. Dylan Hartley, PhD
  • Chief Scientific Officer
  • --
  • Jason A. Leverone
  • Chief Financial Officer and Principal Accounting Officer
  • 2.68M
  • Dr. Andrew Phillips, PhD
  • Chairman of the Board
  • 268.89K
  • Michael Grey
  • Director
  • 333.41K
  • Edward T. Mathers
  • Independent Director
  • 296.58K
  • Dr. Isaac Manke, PhD
  • Independent Director
  • 262.31K
  • Valerie Malyvanh Jansen
  • Independent Director
  • 258.29K
  • R. Michael Carruthers
  • Independent Director
  • 291.30K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More